Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Mereo Biopharma Group Plc ADR (NASDAQ: MREO) closed at $2.92 in the last session, up 0.34% from day before closing price of $2.91. In other words, the price has increased by $0.34 from its previous closing price. On the day, 1.18 million shares were traded. MREO stock price reached its highest trading level at $2.965 during the session, while it also had its lowest trading level at $2.82.
Ratios:
We take a closer look at MREO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.10 and its Current Ratio is at 6.10. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on December 06, 2024, initiated with a Buy rating and assigned the stock a target price of $7.
On June 13, 2024, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $8.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 13 ’24 when Scots-Knight Denise sold 60,046 shares for $4.22 per share. The transaction valued at 253,454 led to the insider holds 808,921 shares of the business.
Scots-Knight Denise sold 28,611 shares of MREO for $127,968 on Sep 12 ’24. The Chief Executive Officer now owns 868,967 shares after completing the transaction at $4.47 per share. On Sep 13 ’24, another insider, Lewicki John A., who serves as the Chief Scientific Officer of the company, sold 10,937 shares for $4.22 each. As a result, the insider received 46,165 and left with 78,630 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MREO now has a Market Capitalization of 453026336 and an Enterprise Value of 2183527680. Its current Enterprise Value per Revenue stands at 2183.528 whereas that against EBITDA is -58.265.
Stock Price History:
The Beta on a monthly basis for MREO is 0.84, which has changed by -0.22399998 over the last 52 weeks, in comparison to a change of 0.23883796 over the same period for the S&P500. Over the past 52 weeks, MREO has reached a high of $5.02, while it has fallen to a 52-week low of $2.53. The 50-Day Moving Average of the stock is -16.44%, while the 200-Day Moving Average is calculated to be -22.05%.
Shares Statistics:
According to the various share statistics, MREO traded on average about 1.01M shares per day over the past 3-months and 1694440 shares per day over the past 10 days. A total of 154.73M shares are outstanding, with a floating share count of 142.11M. Insiders hold about 8.16% of the company’s shares, while institutions hold 62.57% stake in the company. Shares short for MREO as of 1735603200 were 8032628 with a Short Ratio of 7.95, compared to 1732838400 on 6631324. Therefore, it implies a Short% of Shares Outstanding of 8032628 and a Short% of Float of 6.1300002.
